Ampicillin-sulbactam and amikacin used as second-line antibiotics for patients with culture-negative peritonitis.
Lam
Man Fai
MF
Nephrology Division, Department of Medicine, Queen Mary Hospital University of Hong Kong, Hong Kong. feimflam@yahoo.com.hk
Tang
Bone Siu Fai
BS
Tse
Kai Chung
KC
Chan
Tak Mao
TM
Lai
Kar Neng
KN
D000583:Amikacin / Q000008:administration & dosage / Q000627:therapeutic use*; D000667:Ampicillin / Q000008:administration & dosage / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002437:Cefazolin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D007263:Infusions, Parenteral; D010530:Peritoneal Dialysis / Q000009:adverse effects; D010538:Peritonitis / Q000188:drug therapy* / Q000209:etiology / Q000382:microbiology; D019233:Retreatment; D013407:Sulbactam / Q000008:administration & dosage / Q000627:therapeutic use; D014031:Tobramycin / Q000627:therapeutic use; D017211:Treatment Failure; D014640:Vancomycin / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; C035444:sultamicillin; D014640:Vancomycin; D000667:Ampicillin; D000583:Amikacin; D002437:Cefazolin; D013407:Sulbactam; D014031:Tobramycin